Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 17, Issue 3, Pages 763-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/S0889-8588(03)00042-X
Keywords
-
Categories
Funding
- NCI NIH HHS [UO1 CA70054] Funding Source: Medline
Ask authors/readers for more resources
The growing understanding of the interplay between human herpesvirus-8 (HHV-8), HIV type 1 (HIV-1), inflammatory cytokines, and angiogenic factors in the pathogenesis of AIDS-associated Kaposi's sarcoma (KS) provides a coherent (but as yet incomplete) framework for the development of therapeutic strategies that target the mechanisms involved in KS development and progression. There is strong evidence that control of HIV-1 infection can lead to KS regression in some patients, but the mechanism is not defined. Administration of inhibitors of HHV-8 lytic replication is associated with a decrease in subsequent KS incidence, but rarely leads to regression of established KS, which contains primarily latent virus. Thus far, a limited number of clinical trials have been performed with agents that may inhibit cytokines and angiogenic factors associated with KS, and although therapeutic activity has been observed with a number of agents with different targets, many therapeutic approaches remain to be investigated. Given the redundancy of growth factors believed to be involved in K development, it is likely that combinations of agents that target several pathogenetic mechanisms will be more effective than are single drugs in suppressing KS growth.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available